Dabrafenib and Trametinib in Patients With Tumors With BRAF(V600E) Mutations: Results of the NCI-MATCH Trial Subprotocol H

PURPOSE: BRAF(V600) mutations are commonly found in melanoma and thyroid cancers and to a lesser degree in other tumor types. Subprotocol H (EAY131-H) of the NCI-MATCH platform trial sought to investigate the selective BRAF inhibitor dabrafenib and the MEK1/2 inhibitor trametinib in patients with so...

Full description

Saved in:
Bibliographic Details
Published in:J Clin Oncol
Main Authors: Salama, April K. S., Li, Shuli, Macrae, Erin R., Park, Jong-In, Mitchell, Edith P., Zwiebel, James A., Chen, Helen X., Gray, Robert J., McShane, Lisa M., Rubinstein, Larry V., Patton, David, Williams, P. Mickey, Hamilton, Stanley R., Armstrong, Deborah K., Conley, Barbara A., Arteaga, Carlos L., Harris, Lyndsay N., O’Dwyer, Peter J., Chen, Alice P., Flaherty, Keith T.
Format: Artigo
Language:Inglês
Published: American Society of Clinical Oncology 2020
Subjects:
ORIGINAL REPORTS
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7676884/
https://ncbi.nlm.nih.gov/pubmed/32758030
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.00762
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items